GLP-1 receptor agonists and SGLT2 inhibitors are transforming type 2 diabetes care by improving heart, kidney, and stroke outcomes beyond glucose control, but their high cost and limited access raise
> Read more

Updates to the ADA Standards of Care in Diabetes integrate obesity treatment directly into diabetes care.
> Read more

From genetic predispositions to cultural dietary habits and access to healthcare, different ethnic groups experience unique risks, outcomes and health challenges.
> Read more

Nerve disease is one of the most common diabetes-related complications, occurring in approximately 1 in 2 people living with the condition.
> Read more